<table class="wikitable"><tr><th> Antibody </th><th> Brand name </th><th> Approval date </th><th> Type </th><th> Target </th><th> Approved treatment(s) </th></tr><tr><td> Alemtuzumab </td><td> Campath </td><td> 2001 </td><td> humanized </td><td> CD52 </td><td> Chronic lymphocytic leukemia </td></tr><tr><td> Bevacizumab </td><td> Avastin </td><td> 2004 </td><td> humanized </td><td> vascular endothelial growth factor </td><td> colorectal cancer </td></tr><tr><td> Brentuximab vedotin </td><td> Adcetris </td><td> 2011 </td><td> chimeric </td><td> CD </td><td> Hodgkin lymphoma , Anaplastic large-cell lymphoma </td></tr><tr><td> Cetuximab </td><td> Erbitux </td><td> 2004 </td><td> chimeric </td><td> epidermal growth factor receptor </td><td> colorectal cancer </td></tr><tr><td> Gemtuzumab ozogamicin </td><td> Mylotarg </td><td> 20 </td><td> humanized </td><td> CD33 </td><td> acute myelogenous leukemia (with calicheamicin ) </td></tr><tr><td> Panitumumab </td><td> Vectibix </td><td> 2006 </td><td> human </td><td> epidermal growth factor receptor </td><td> colorectal cancer </td></tr><tr><td> Rituximab </td><td> Rituxan, Mabthera </td><td> 1997 </td><td> chimeric </td><td> CD </td><td> non-Hodgkin lymphoma </td></tr></table>
